Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy entities : Bridgebio pharma, inc. save search
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
Published: 2023-10-03 (Crawled : 12:00) - bridgebio.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.0%
H: 1.4%
C: 0.08%
bbp-631 partnership multi-year bbp-812 therapy
BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Published: 2023-05-22 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.73%
H: 1.66%
C: -0.8%
bbp-812 pharma disease biomarker cell meeting program therapy
BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Published: 2023-05-15 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.41%
H: 10.0%
C: 9.12%
bbp-812 pharma disease cell meeting program therapy
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
Published: 2022-06-22 (Crawled : 12:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.02%
H: 12.96%
C: 8.61%
bbp-812 pharma disease aav9 positive therapy
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Published: 2022-05-20 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 3.42%
H: 2.83%
C: 2.7%
ptr-01 treatment pharma trial positive therapy
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
Published: 2022-01-27 (Crawled : 13:30) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 1.03%
H: 1.33%
C: -9.04%
renal gene therapy trial phase 1 therapy
Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes
Published: 2022-01-13 (Crawled : 13:30) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -5.11%
H: 1.25%
C: -4.2%
therapy
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease
Published: 2021-11-03 (Crawled : 12:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.2%
H: 0.0%
C: 0.0%
disease phase 1 gene therapy therapy trial phase 2
BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers
Published: 2021-10-29 (Crawled : 13:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.02%
H: 0.16%
C: -2.24%
disease genetic potential collaboration cancer announces collaboration therapy
BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers
Published: 2021-10-12 (Crawled : 12:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.13%
H: 2.4%
C: -0.13%
disease genetic gene therapy therapy cancer
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Published: 2021-09-15 (Crawled : 12:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.47%
H: 1.06%
C: -1.02%
treatment fda fda fast track fast track therapy fast track designation designation
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia
Published: 2021-05-14 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.32%
H: 6.01%
C: 5.46%
fda fda fast track fast track renal gene therapy therapy gene therapies fast track designation designation pharma
BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases
Published: 2021-04-13 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.43%
H: 2.42%
C: 0.76%
disease genetic collaboration research therapy
BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers
Published: 2021-04-13 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.43%
H: 2.42%
C: 0.76%
genetic collaboration cancer research therapy pharma
BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.43%
H: 2.42%
C: 0.76%
disease genetic potential collaboration research therapy
BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
Published: 2021-02-28 (Crawled : 13:03) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
| Email alert
Add to watchlist
fda risk fda approval therapy approval
UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases
Published: 2020-12-23 (Crawled : 13:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.0%
H: 2.41%
C: 1.74%
disease collaboration therapy pharma
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.